Taysha Gene Therapies Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | – | – | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 67.1% | 13.4% | 29.4% | 7.0% | 10.2% | 9.5% | 27.0% | – | -30.9% | – | 13.9% | – | 5.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 32.9% | 86.6% | 70.6% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 94.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 554.0% | 265.9% | 826.3% | 248.4% | 351.9% | 605.6% | 1,355.5% | 835.9% | 757.9% | 676.2% | 1,014.1% | – | 449.5% | – | – | 2,234.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 293.4% | 186.0% | 250.0% | 181.0% | 186.4% | 207.7% | 659.9% | 441.9% | 327.8% | 354.4% | 432.9% | – | 161.0% | – | – | 709.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 847.4% | 438.5% | 1,047.0% | 422.4% | 550.8% | 813.3% | 2,015.4% | 1,548.4% | 1,085.8% | 1,030.5% | 1,447.1% | – | 610.5% | – | – | 2,876.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | -2,203.0% | -351.9% | -976.4% | -329.4% | -450.8% | -713.3% | -1,915.4% | -1,448.4% | -985.8% | -930.5% | -1,347.1% | – | -516.0% | – | – | -2,792.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 31.8% | 29.2% | 60.1% | 31.0% | 19.8% | 0.9% | 2.4% | 1.3% | 1.1% | 0.8% | 0.9% | – | 0.2% | – | – | 0.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | -2,227.1% | -374.5% | -1,027.1% | -2,467.1% | 1,324.7% | -705.4% | -1,882.0% | -1,427.5% | -929.0% | -935.2% | -1,353.6% | – | -507.8% | – | – | -2,728.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 93.3% | 51.8% | 60.3% | -7.0% | -98.5% | 8.3% | – | – | -13.9% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -2,320.4% | -374.5% | -1,027.1% | -2,467.1% | 1,324.7% | -705.4% | -1,882.0% | -1,427.5% | -929.0% | -935.2% | -1,353.6% | – | -507.8% | – | – | -2,728.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | -739.7% | -331.9% | -937.6% | -2,429.1% | 1,354.6% | -695.0% | -1,850.6% | -1,409.7% | -912.9% | -922.1% | -1,338.8% | – | -510.5% | – | – | -2,712.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.